BH.IMMUN&BIO | BERYL DRUGS | BH.IMMUN&BIO/ BERYL DRUGS |
|||
---|---|---|---|---|---|
P/E (TTM) | x | -7.7 | 15.1 | - | View Chart |
P/BV | x | 1.5 | 2.2 | 68.1% | View Chart |
Dividend Yield | % | 0.0 | 0.0 | - |
BH.IMMUN&BIO BERYL DRUGS |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
BH.IMMUN&BIO Mar-23 |
BERYL DRUGS Mar-23 |
BH.IMMUN&BIO/ BERYL DRUGS |
5-Yr Chart Click to enlarge
|
||
High | Rs | 52 | 18 | 287.8% | |
Low | Rs | 21 | 8 | 273.3% | |
Sales per share (Unadj.) | Rs | 10.3 | 53.0 | 19.5% | |
Earnings per share (Unadj.) | Rs | -3.9 | 1.5 | -255.0% | |
Cash flow per share (Unadj.) | Rs | -3.8 | 3.1 | -122.2% | |
Dividends per share (Unadj.) | Rs | 0 | 0 | - | |
Avg Dividend yield | % | 0 | 0 | - | |
Book value per share (Unadj.) | Rs | 20.4 | 15.9 | 128.4% | |
Shares outstanding (eoy) | m | 43.18 | 5.07 | 851.7% | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 3.5 | 0.2 | 1,455.0% | |
Avg P/E ratio | x | -9.4 | 8.4 | -111.1% | |
P/CF ratio (eoy) | x | -9.5 | 4.1 | -232.1% | |
Price / Book Value ratio | x | 1.8 | 0.8 | 220.7% | |
Dividend payout | % | 0 | 0 | - | |
Avg Mkt Cap | Rs m | 1,561 | 65 | 2,413.9% | |
No. of employees | `000 | NA | NA | - | |
Total wages/salary | Rs m | 151 | 15 | 1,018.5% | |
Avg. sales/employee | Rs Th | 0 | 0 | - | |
Avg. wages/employee | Rs Th | 0 | 0 | - | |
Avg. net profit/employee | Rs Th | 0 | 0 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 446 | 269 | 165.9% | |
Other income | Rs m | 11 | 3 | 381.3% | |
Total revenues | Rs m | 457 | 272 | 168.1% | |
Gross profit | Rs m | -161 | 20 | -808.7% | |
Depreciation | Rs m | 2 | 8 | 24.6% | |
Interest | Rs m | 71 | 5 | 1,511.8% | |
Profit before tax | Rs m | -223 | 10 | -2,263.0% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | -56 | 2 | -2,582.1% | |
Profit after tax | Rs m | -166 | 8 | -2,172.2% | |
Gross profit margin | % | -36.0 | 7.4 | -487.5% | |
Effective tax rate | % | 25.3 | 22.1 | 114.2% | |
Net profit margin | % | -37.3 | 2.8 | -1,309.3% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 358 | 104 | 343.9% | |
Current liabilities | Rs m | 940 | 64 | 1,464.1% | |
Net working cap to sales | % | -130.6 | 14.8 | -880.3% | |
Current ratio | x | 0.4 | 1.6 | 23.5% | |
Inventory Days | Days | 85 | 14 | 603.3% | |
Debtors Days | Days | 1,135 | 937 | 121.2% | |
Net fixed assets | Rs m | 1,262 | 71 | 1,785.1% | |
Share capital | Rs m | 432 | 51 | 847.7% | |
"Free" reserves | Rs m | 450 | 30 | 1,514.8% | |
Net worth | Rs m | 882 | 81 | 1,093.7% | |
Long term debt | Rs m | 0 | 27 | 0.0% | |
Total assets | Rs m | 1,620 | 175 | 926.7% | |
Interest coverage | x | -2.2 | 3.1 | -69.3% | |
Debt to equity ratio | x | 0 | 0.3 | 0.0% | |
Sales to assets ratio | x | 0.3 | 1.5 | 17.9% | |
Return on assets | % | -5.9 | 7.1 | -83.9% | |
Return on equity | % | -18.9 | 9.5 | -198.6% | |
Return on capital | % | -17.2 | 13.4 | -128.2% | |
Exports to sales | % | 0 | 0 | - | |
Imports to sales | % | 14.5 | 0 | - | |
Exports (fob) | Rs m | NA | NA | - | |
Imports (cif) | Rs m | 65 | NA | - | |
Fx inflow | Rs m | 0 | 0 | - | |
Fx outflow | Rs m | 65 | 0 | - | |
Net fx | Rs m | -65 | 0 | - |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 109 | 25 | 439.2% | |
From Investments | Rs m | 5 | -13 | -35.5% | |
From Financial Activity | Rs m | -147 | -12 | 1,260.7% | |
Net Cashflow | Rs m | -34 | 0 | -27,975.0% |
Indian Promoters | % | 59.3 | 26.4 | 224.6% | |
Foreign collaborators | % | 0.0 | 0.0 | - | |
Indian inst/Mut Fund | % | 0.0 | 0.0 | - | |
FIIs | % | 0.0 | 0.0 | - | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 40.8 | 73.6 | 55.4% | |
Shareholders | 35,313 | 7,257 | 486.6% | ||
Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare BH.IMMUN&BIO With: DIVIS LABORATORIES CIPLA SUN PHARMA DR. REDDYS LAB ZYDUS LIFESCIENCES
No comparison is complete without understanding how the stock prices have performed over a period of time.
Here's a brief comparison:
Period | BH.IMMUN&BIO | BERYL DRUGS | S&P BSE HEALTHCARE |
---|---|---|---|
1-Day | -2.23% | -0.20% | 0.31% |
1-Month | -2.23% | 15.24% | 0.08% |
1-Year | 28.97% | 163.45% | 54.11% |
3-Year CAGR | -13.27% | 82.46% | 14.46% |
5-Year CAGR | 30.36% | 37.64% | 20.04% |
* Compound Annual Growth Rate
Here are more details on the BH.IMMUN&BIO share price and the BERYL DRUGS share price.
Moving on to shareholding structures...
The promoters of BH.IMMUN&BIO hold a 59.3% stake in the company. In case of BERYL DRUGS the stake stands at 26.4%.
To review how promoter stakes have changed over time, and how much of the promoter stake is pledged, please see the shareholding pattern of BH.IMMUN&BIO and the shareholding pattern of BERYL DRUGS.
Finally, a word on dividends...
In the most recent financial year, BH.IMMUN&BIO paid a dividend of Rs 0.0 per share. This amounted to a Dividend Payout ratio of -0.0%.
BERYL DRUGS paid Rs 0.0, and its dividend payout ratio stood at 0.0%.
You may visit here to review the dividend history of BH.IMMUN&BIO, and the dividend history of BERYL DRUGS.
For a sector overview, read our pharmaceuticals sector report.
After opening the day on positive note, Indian share markets continued the momentum as the session progressed and ended higher.